<DOC>
	<DOCNO>NCT00910793</DOCNO>
	<brief_summary>The objective study evaluate effect combination formoterol beclometasone dipropionate central peripheral airway dimension asthmatic patient use Computational Fluid Dynamics ( CFD ) . Further , effect combination therapy exhale NO , lung function ( spirometry , body plethysmography , diffusion resistance ) subjective asthma control score well safety combination assess .</brief_summary>
	<brief_title>Study Assess Effect Formoterol Beclomethasone Dipropionate Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Patients asthma define current Global INitiative Asthma ( GINA ) guideline : Male female patient age ≥18 year Patients document positive response reversibility test within 12 month precede screen visit perform screen visit washout 2 day long act β2 agonist document positive response methacholine challenge test Patients cooperative attitude ability train correctly use pressurize Metered Dose Inhaler ( pMDI ) Written informed consent obtain Pregnant lactate female female risk pregnancy Inability carry pulmonary function test Diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) define current Global initiative chronic Obstructive Lung Disease ( GOLD ) guideline History near fatal asthma Hospitalization due asthma symptomatic infection airways previous 8 week Current smoker recent ( less one year ) exsmokers , define smoke least 10 cigarettes/day Patients uncontrolled disease condition might , judgement investigator , place patient undue risk potentially compromise result interpretation study Patients QTc interval ( Bazett 's formula ) screen visit Electrocardiogram ( ECG ) test &gt; 450 msec Cancer chronic disease poor prognosis /or affect patient status History alcohol drug abuse Allergy , sensitivity intolerance study drug and/or study drug formulation ingredient Patients unlikely comply protocol unable understand nature , scope possible consequence study Patients receive investigational new drug within last 8 week prior screen visit Patients treat nonpermitted concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Formoterol</keyword>
	<keyword>Beclomethasone Dipropionate</keyword>
	<keyword>Computational Fluid Dynamics</keyword>
	<keyword>Functional Imaging</keyword>
	<keyword>Central Peripheral Airways</keyword>
</DOC>